Indirect Comparison Showed Survival Benefit from Adjuvant Chemoradiotherapy in Completely Resected Gastric Cancer with D2 Lymphadenectomy

Table 1

Characteristics of selected RCTs.

References	Countries	Regimens	𝑁	I/II/III/IV (%)	T3/4 (%)	N+ (%)	DFS	OS	Median (range)	Jadad score
							HR (95% CI)	HR (95% CI)	Follow-up (month)
Chemoradiotherapy versus chemotherapy
Lee et al.; 2012 [12]	Korea	XP/XRT/XP	230	21.3/36.5/30.8/11.3	NR	88.3	0.73 (0.52–1.04)	—	53.2 (36.9–77.3)	3
		XP	228	21.9/37.7/28.6/11.8	NR	84.6
Zhu et al. 2012 [13]	China	RT/FL	168	10.8/19.4/55.4/14.5	100	84.9	0.74 (0.56–0.97)	0.80 (0.6–1.06)	42.5	3
		FL	165	9.1/18.2/58.2/14.5	100	86.7
Kim et al. 2012 [14]	Korea	RT/FL	46	0/0/73.9/26.1	69.5	100	0.62 (0.33–1.14)	0.76 (0.39–1.48)	86.7 (60.3–116.5)	3
		FL	44	0/0/75/25	56.8	95.4
Observation versus chemotherapy
Cirera et al. 1999 [15]	Spain	MMC/tegafur	76	0/0/100/0	92	80	1.82 (1.18, 2.79)	1.67 (1.08, 2.57)	37 (3–122)	4
		Observation	72	0/0/100/0	89	97
Nakajima et al. 2007 [16]	Japan	Uracil-tegafur	93	0/100/0/0	0	100	2.27 (1.28, 1.04)	2.08 (1.13, 3.85)	74.4	5
		Observation	95	0/100/0/0	0	100
Sasako et al. 2011 [17]	Japan	S-1	529	0.2/49.9/42.3/7.6	45.1	90.4	1.54 (1.27, 1.86)	1.49 (1.20, 1.85)	60	3
		Observation	530	0/53.2/40.2/6.6	46.1	87.9
Bang et al. 2012 [18]	Korea	XELOX	520	1/49/51/0	45	91	1.79 (1.40, 2.28)	1.39 (1.00, 1.93)	34.2 (25.4–41.7)	3
		Observation	515	0/51/49/0	45	89

RCTs: randomized controlled trials; 𝑁: number of patients; I/II/III/IV: cancer stage; IV refers to T4N1-3M0 and T1-3N3M0; T3/4: percentage of T3 and T4 stage; N+: percentage of node positive; DFS: disease-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval.
NR: not report.
XP: capecitabine + cisplatin; XRT: radiotherapy with capecitabine; RT: radiotherapy; FL: fluorouracil plus leucovorin; MMC: mitomycin; XELOX: oxaliplatin + capecitabine.